Clinical Trial Update: A Study of Enicepatide (CT-388) in Participants With Obesity or Overweight With at Least One Weight-Related Comorbidity [Phase 2]

View source ↗

Summary

Phase 2 study of Enicepatide (CT-388) in adults with obesity or overweight and at least one weight-related comorbidity has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• Enicepatide (CT-388) (Enicepatide)

Snippet

Sponsor: Carmot Therapeutics, Inc. | Conditions: Obesity, Overweight | Phase 2 | Status: COMPLETED